Dr. Reddy’s moves first in Canada’s generic semaglutide market. Can access improve?
GLP-1 demand is booming, but access remains uneven. Dr. Reddy’s Canada launch tests whether generics can change semaglutide economics.
Pharma & Biotech
Pharma & Biotech
Can Apotex crack the complex generic code for semaglutide before the glucagon-like peptide-1 market resets?
Apotex won first tentative U.S. approval for generic semaglutide. Read what it could mean for glucagon-like peptide-1 access, pricing, and competition.